TG reports updated Phase IIa MS data for anti-CD20 mAb

TG Therapeutics Inc. (NASDAQ:TGTX) reported updated data from a Phase IIa trial evaluating ublituximab (TG-1101, TGTX-1101) to treat relapsing multiple sclerosis. Ublituximab is a glycoengineered mAb against CD20.

Among 38 evaluable patients with relapsing MS, ublituximab reduced the mean number of T1 gadolinium-enhancing lesions to 0 at week 24 from 2.68 at baseline (p=0.0005). Among 40 evaluable patients, 97.5% of patients were relapse free at week 24. Ublituximab also led to 99% median B cell depletion at week four, which was maintained to week 24...